



XDx to Present at 25th Annual JPMorgan Healthcare Conference

Brisbane, Calif., January 5, 2007 – XDx, a molecular diagnostics company, announced today that Pierre Cassigneul, president and chief executive officer, will be presenting at the 25th Annual JPMorgan Healthcare Conference on Monday, January 8, 2007, at 11 a.m. Pacific Time. The conference will be held January 8-11, 2007, at the Westin St. Francis hotel in San Francisco.

About XDx

XDx's mission is to improve patient care by developing molecular diagnostics that translate an individual's immune status into clinically actionable information.

Founded in 2000, XDx is a molecular diagnostics company that utilizes state-of-the-art genomic technology and sophisticated bioinformatics analyses to understand and measure the immune processes that underlie specific disease conditions. Physicians can use this information to optimize patient treatment and minimize the long-term consequences of immunosuppressive therapies. More information can be found at www.xdx.com.

About AlloMap® Molecular Expression Testing

The first product of this unique approach is AlloMap® molecular expression testing. This service, offered through the XDx CLIA-certified laboratory since January 2005, is being used by many leading cardiac transplant centers in the United States to monitor patients following their heart transplants. The scientific and clinical validation of this technology has been described in a peer-reviewed article published in the *American Journal of Transplantation* in 2006.

XDx's science and technology is now being evaluated in patients with other solid organ transplants. Building on the discoveries made during the development of AlloMap testing for heart transplant patients, which included the identification of many genes and pathways involved in tissue rejection, XDx is now developing a product for use by physicians to better manage lung transplant patients.

Beyond the use of AlloMap testing in assessing immune reaction in solid organ transplantation, XDx scientists are applying similar approaches to create new molecular diagnostics tests for the improved clinical management of immune-mediated inflammatory diseases, such as systemic lupus erythematosus (SLE or lupus,) to diagnose and predict clinical flares common in a variety of these diseases.

In addition to its potential for use by physicians for better patient management, the XDx approach is of interest to pharmaceutical companies looking to use biomarkers predictive of drug efficacy in order to proactively identify patient response and to better target their drug development efforts and clinical trials. More information can be found at www.allomap.com.

#

CONTACT:

Corporate:
Tammy Reilly
XDx
415-287-2300

Media:
Kelly McKenna
MS&L
415-293-2808